
Conference Coverage
about 11 hours ago
Ensitrelvir PEP Lowers Viral Load in COVID-19 Breakthrough InfectionsLatest Content

Low CRC Incidence Found After Endoscopic Mucosal Resection

FDA Approves Obinutuzumab as First Therapy for Membranous Nephropathy

Complicated UTI Care Strained by Unclear Goals, Access Gaps

Aficamten Reduces LV Mass, Wall Thickness in Nonobstructive HCM

FDA Approves Oral Giredestrant Regimen for ESR1-Mutated Breast Cancer

Shorts










Center on Health Equity & Access
All News

New York hepatitis B experts say screening gaps and weekly monitoring demands could limit who benefits from the first functional cure therapy.

Phase 3 OASIZ-301 data at ACR 2026 show dazodalibep lowered systemic activity in Sjögren disease, with dryness gains at the every-4-weeks dose.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

Cardiologists and pharmacy leaders explained how team-based clinics and standardized paperwork are speeding obstructive HCM treatment.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

San Francisco experts say payer step edits and weak biologic follow-up slow atopic dermatitis care and point to pharmacy teams and dashboards.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.

In the years since the first approval for CAR T-cell therapy, major managed care plans have adopted mechanisms to include these treatments. But many employer-sponsored plans may not be required to cover them, and such treatments are "lasered out."





























